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Abstract 
Tumors are believed to consist of a heterogeneous population of tumor cells 
originating from rare cancer stem cells (CSCs). However, emerging evidences show that 
tumor may also originate from non-CSCs. Here, we give evidences supporting that the 
number of tumorigenic tumor cells is higher than the number of CSCs and tumor can also 
derive from non-CSCs. First, we applied an idealized mathematical model and 
theoretically calculated that non-CSCs could initiate tumor if their proliferation potential 
was adequate. Next, we demonstrated by experimental studies that 17.7%, 38.6% and 
5.2% of tumor cells in murine B16 solid melanoma, H22 hepatoma and Lewis lung 
carcinoma, respectively, were potentially tumorigenic. We propose that the rare CSCs, if 
exist, are not the only origination of a tumor. 
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1. Introduction 
Tumors are comprised of phenotypically diverse populations of tumor cells, and some 
of them are highly tumorigenic than others (1). It is now widely believed that many of 
cancers are derived from a rare subpopulation of cells, designated cancer stem cells 
(CSCs), or cancer-initiating cells (2). By definition, cancer stem cells are self-renewing 
cells that are responsible for sustaining a cancer and for producing differentiated progeny 
that form the bulk of the cancer, while cancer-initiating cell is a general term that 
encompasses both cancer cell of origin (precancerous cell that gives rise to a cancer stem 
cell) and cancer stem cell (3). However, CSCs always have the same meaning as 
cancer-initiating cells in many literatures (2, 4). The concept of CSC has been 
demonstrated in many human cancers including melanoma (5), lung (6), liver (7), and 
colon caners (4), and so on. Like stem cells from their normal counterpart, CSCs (or 
cancer-initiating cells) are a rare population, and they are self-renewing and capable of 
unlimited proliferation. Tumors are believed to be generated from such rare CSCs (1, 2). If 
the CSC hypothesis is correct, it will usher in an era of hope for curing once-incurable 
cancers by targeting CSC. However, not everyone accepts the hypothesis of CSC. 
Recently a paper challenged the concept of CSC because the authors concluded that 
tumor growth needed not be driven by rare CSC (8). Using nonirradiated histocompatible 
recipient mice (not sublethally irradiated nonobese diabetic severe combined 
immunodeficient mice that usually were used in the studies of CSC identification), the 
authors observed that a large proportion of primary tumor cells can sustain the growth of 
murine lymphoid and myeloid malignancies. More recently, a study showed that in 
single-cell transplants, an average of 27% of unselected melanoma cells from four 
different patients could form tumors in highly immunocompromised mice, and thus the 
frequency of tumorigenic cells in human melanoma was much higher than reported for 
any cancer previously suggested to follow a cancer stem-cell model (9). 
Thus, the concept of CSC seems somewhat controversial. Is the concept of CSC 
correct that the tumor growth need just be driven by rare CSC, or the tumor growth need 
not be driven just by CSC? In the present study, we provide evidences supporting that the 
number of tumor cells capable of generating a new tumor is higher than the number of 
CSCs. We give the definition of tumorigenic cells as the tumor cells capable of generating 
a new tumor. Tumorigenic cells encompass both CSCs and others tumor cells that can 
generate a new tumor in vivo. Although the CSCs might exist, they might not be the only 
ones to generate tumors. Therefore, during tumor therapy, it seems necessary to target all 
tumor cells that have a high proliferation potential and not only CSCs. 
 
 
2. Material and methods  
2.1. Mathematical model and calculation 
The theoretical probability of CSC in a population of tumor cells was calculated by using traditional 
mathematic tools. To easily understand and calculate, we also used an idealize CSC differentiation 
model (Fig. 1). 
2.2. Mice and Tumor Models 
Animal experiments involving mice were approved by the institute's Animal Care and Use 
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Committee. Mice were maintained under standard conditions. To generate solid melanoma, C57BL/6 
mice were inoculated with B16 melanoma cells by the subcutaneous injection of 2×106 cells into the 
dorsal skin. To generate solid hepatoma, BALB/c mice were inoculated with H22 hepatoma cells by the 
injection of 5×105 cells into the hind thigh muscle. To generate solid lung cancer, C57BL/6 mice were 
inoculated with Lewis lung carcinoma (LLC) cells by the axillary injection of 2×106 cells.  
2.3. Single tumor cell preparation 
Tumors (1 cm in diameter) were minced into 2–3-mm pieces and digested for 2 h at 37°C in DMEM 
containing type IV collagenase (0.1%; Sigma), type I DNase (0.002%; Sigma), and type V hyaluronidase 
(0.01%; Sigma) and single-cell suspension was prepared. The cells were then washed twice with PBS for 
5 min at 120 g. 
Further removing of blood cells and dead cells by magnetic activated cell-sorting was performed as 
described previously (10). Briefly, to remove leukocytes and erythrocytes, biotinylated anti-CD45.2 and 
anti-TER119 monoclonal antibodies (eBioscience) were used. To remove dead cells, we used Dead Cell 
Removal MicroBeads (Milteny Biotec) following the manufacture’s protocol. After the antibody labeling, 
cells were resuspended in 80 μl of buffer (PBS containing 0.5% BSA and 2 mM EDTA) per 107 total 
cells and incubated with anti-biotin microbeads for 15 min at 6-12 ℃. Cells were washed twice and finally 
resuspended in 500 μl of buffer per 107 total cells. A pre-moistened MS column (Milteny Biotec) was 
placed in the magnetic field of a suitable MACS separator. The cell suspension was applied onto the 
column and effluents were collected as the purified tumor cells. Viability of sorted tumor cells exceeded 
98% as assessed by trypan blue exclusion. 
2.4. In vitro colony assay 
Purified tumor cells were plated on 96-well plates at a density of 1 cell per well and maintained at 
37°C, 5% CO2. The medium was DMEM supplemented with 15% FCS and 100 U/ml 
penicillin-streptomycin. Two weeks later, the large colonies were digested (if B16 and LLC cells) and 
transferred to new culture dishes. 
2.5. Tumor cell inoculation and tumor surveillance 
Mice were inoculated with different doses of tumor cells in 100 μl of PBS. Tumor surveillance was 
performed as described previously (11). Tumor size was measured using calipers fitted with a Vernier 
scale when tumor could be palpated. The tumor diameter was calculated using the formula (a + b)/2, with 
a as the larger diameter and b as the smaller diameter. Mice were sacrificed 100 days after inoculation or 
for ethical reasons when tumors exceeded 1.2 cm in diameter. All tumor tissues were examined and 
verified by hematoxylin-eosin staining.  
 
 
3. Results  
3.1. Theoretical calculation of CSC probability 
CSCs are a very rare population in the tumor (1, 2). For example, there is only one 
cancer-initiating cell in 5.7×104 unfractionated human colon tumor cells (4). According to 
the CSC theory, the tumor formation depends on the existence of CSC, or cancer is 
maintained by CSC. In other words, if a small tumor cell population taken from a tumor 
contains at least one CSC, then, theoretically, a new tumor could be generated from such 
population of tumor cells. If there are 10n CSCs in a 1-cm3 tumor mass which contains 
approximately 109 tumor cells, then the probability that there is at least one CSC in any 
10m tumor cells taken from such 109 tumor cells can be calculated using binomial 
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distribution (12) as follows. 
The probability that there is no CSC in any 10m tumor cells taken from such 109 tumor 
cells is: 
 
Then, the probability that there is at least 1 CSC in any 10m tumor cells taken from the 
109 tumor cells is: 
p = (1 – p’) × 100%  
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Based on the past experience of tumor inoculation, nearly 100% of mice inoculated 
with any 105 (or more) unsorted tumor cells would develop a tumor. By applying the above 
formula, we calculate that there are about 104 CSCs in a 1-cm3 tumor mass, i.e., the 
proportion of CSC in the tumor is about 10-5, which is a value close to that obtained from 
the experimental study of human colon cancer (1 CSC in about 5.7×104 colon cancer cells 
(4)). Theoretically, if the proportion of CSC is 1%, then the probability that there is at least 
one CSC in any 100 tumor cells taken from a 1-cm3 tumor mass is 0.63 (63%). The 
observations of experiments involving inoculation with tumor cells reveal that any 100 
tumor cells from a 1-cm3 tumor mass cannot usually generate a new tumor; thus, the 
actual proportion of CSCs in a tumor is below 1%. 
Theoretically, a 1-cm3 tumor mass could be generated from one CSC after 30 cell 
doublings (230 ≈ 109，Fig. 1). If the proportion of CSC is 10-5, the theoretical division times 
to generate a 1-cm3 tumor mass should be about 17 (109 ≈ 104 × 217). 
Although a CSC (the zero differentiation level, Fig. 1) is self-renewing and capable of 
unlimited proliferation, the proliferation potential of CSCs after 1 passage (the 1st 
differentiation level, Fig. 1) should be determined. Theoretically, if cells at the 1st 
differentiation level can divide 30 times, then 1 such cell can generate a 1-cm3 new tumor 
mass after in vivo inoculation (230 ≈ 109). Further, if the cells at the 1st differentiation level 
had a higher proliferation potential (for example, 32 divisions), then the cells at the 2nd and 
3rd differentiation levels would have the potential to generate a 1-cm3 tumor mass after in 
vivo inoculation. If the cells at the 1st differentiation level in the model in Fig. 1 were 
capable of dividing 30 + y times, then the proportion of the cells in a 1-cm3 tumor mass 
that could generate a 1-cm3 new tumor is 2–30 + 2–30 + 2–29 + … + 2y–30, i.e., 2y–29 (y ≤ 29). 
Taken together, the higher the proliferation potential (＞30 divisions) of the cells at the 1st 
differentiation level, the higher the proportion of cells with the potential to generate a 
1-cm3 new tumor in a cell population. If y = 23, then theoretically, according to the model in 
Fig. 1, there will be more than 1% (i.e., 2y–29 = 2–6 = 0.016) of tumor cells with the potential 
to generate a 1-cm3 new tumor. Meanwhile, the proportion of CSCs was merely 2–30. In 
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other words, the number of tumor cells capable of generating a new tumor is higher than 
the number of CSCs. Interestingly, such theoretical speculation conforms to the results of 
two recent studies (8, 9). 
 
 
Figure 1. An idealized model of CSC differentiation. In fact, this model is not new and is well accepted 
by many people. In this model, CSCs (differentiation level 0) divide asymmetrically to self-renew and 
gives rise to a more differentiated progeny (differentiation level 1) that divide symmetrically and give rise 
to 2 more differentiated tumor cells. After n divisions (differentiation level n is the terminal differentiation 
level), the total number of cells derived from a single CSC would be 2n. 
 
 
Of course, we should note that biologically a growing cell population may yield 
intra-tumoral quiescence (13, 14) and hence sub-exponential growth and the final 
tumor size should be smaller than the theoretical size. Thus, to generate a 1-cm3 new 
tumor in vivo, actually one stem cell should divide much more than 30 times, and we could 
speculate that the cells at the 1st differentiation level should also have a higher 
proliferation potential (also much more than 30 divisions) than the theoretical potential. 
Therefore, the number of tumor cells theoretically capable of generating a new tumor 
would be more than the calculated number as described above. 
 
3.2. A large population of tumor cells in B16 solid melanoma was potentially 
tumorigenic 
To further evaluate whether the tumor formation depends on the existence of CSCs, 
we needed to detect the potential tumorigenicity of any tumor cell in a tumor and examine 
if the number of tumor cells capable of generating a new tumor is higher than the number 
of CSCs. First we performed in vitro single-cell culture of tumor cells from murine B16 
solid melanoma. We found that most of the B16 tumor cells died in a few days, while some 
formed small colonies but stopped proliferating after several days, indicating that they 
were possibly composed of terminally differentiated cells (Fig. 2, a and b). Meanwhile, 
there were large colonies containing ＞1000 cells formed in 2 weeks from 17.7% of the 
initial cultured B16 tumor cells (Fig. 2, c). The large colonies continued to proliferate after 
passaging. When the number of passaged cells from each large colony reached about 106, 
we inoculated immunocompetent syngeneic C57BL/6 mice with the tumor cells from some 
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randomly selected colonies at a dose of 7.5 × 105 or 1.5 × 105 cells per mouse. We found 
that all the mice (13/13) developed melanoma at these inoculation doses, and all the 
tumors had diameters greater than 1 cm within 22 days (Fig. 3). When the tumors could 
be palpated, the tumor growth rate was similar between the 2 groups of mice inoculated 
with 7.5 × 105 or 1.5 × 105 cells, although the onset of tumor formation was delayed in the 
mice inoculated with 1.5 × 105 cells (Fig. 3, b). However, when the mice received only 750 
cells from the same colonies, only 2 of 7 mice developed melanoma in 100 days (Fig. 3, a), 
indicating that the capacity of tumor generation from a tumor cell colony depends mainly 
on the number of inoculated cells and that a small number of cells may not be capable of 
adapting and proliferating in vivo in order to form a tumor. In fact, in the previous studies 
that identified CSCs (4, 5, 7, 15), inoculation with at least 10–100 or more tumor cells and 
not just 1 CSC was required to generate a new tumor, although theoretically a tumor could 
be generated after inoculation with a single CSC. Taken together, these results indicate 
that if only a few tumor cells, even if they are CSCs, are used for inoculation, they can only 
barely generate a tumor. Furthermore, more importantly, our results indicate that there are 
17.7% of tumor cells in B16 melanoma with the potential to generate a new melanoma. 
Under suitable growth conditions (in vitro culture condition in these experiments) that 
support the proliferation of these single tumor cells to achieve a certain cell number, these 
cells can generate a tumor in vivo. Thus, similarly, if the microenvironment of any in vivo 
system is suitable for the growth of these single tumor cells, they may proliferate and 
generate a new tumor within that environment. Obviously, all the 17.7% of B16 tumor cells 
might have a high proliferation potential that they could divide >30 times and thus form a 
tumor in vivo.  These 17.7% of B16 tumor cells might encompass the CSCs of B16 tumor 
(differentiation level 0, Fig. 1) and some of their offspring cells (differentiation level 1 and 
more, Fig. 1). According to the idealized model in Fig. 1 and the actual proportion of CSCs 
in a tumor (for example, 1/105), the cells at the 1st differentiation level in B16 melanoma 
should have a proliferation potential that they can undergo 43–56 divisions (If there is only 
one CSC in a 1-cm3 tumor, then 2y–29 = 0.177, y ≈ 26, and the proliferation potential is 
30 + y = 56; if the proportion of CSC is 1/105, then there are 104 (104 ≈ 213) CSCs in a 
1-cm3 tumor, and the proliferation potential of the 1st differentiation level is 56 – 13 = 43). 
 
 
Figure 2. Colony culture of B16 melanoma cells in vitro. Single tumor cells from a murine B16 solid 
melanoma were cultured in vitro for 2 weeks, and 3 representative photographs of clonal colonies of 
different sizes are shown. Bar: 50 μm (a) and 100 μm (b and c). 
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Figure 3. Tumor formation of B16 melanoma cells in vivo. Mice were inoculated with tumor cells from 
different clonal colonies at the indicated doses and tumor formation was monitored for 100 days (a). The 
individual tumor diameter was measured twice a week and the mean tumor diameters of two groups were 
shown in b. 
 
 
3.3. A large population of tumor cells in either Lewis lung carcinoma or H22 
hepatoma was potentially tumorigenic 
Next, we evaluated whether other types of tumors have characteristics similar to that 
of B16 melanoma. We performed similar experiments using in vitro single-cell cultures 
and tumor cell inoculation experiments for murine Lewis lung carcinoma (LLC) and H22 
hepatoma. We found that 5.2% of the LLC solid tumor cells could form large clonal 
colonies in vitro (data not shown). Further, the tumor cells from these colonies could 
generate new tumors in vivo when inoculated at high doses into immunocompetent 
syngeneic mice (Fig. 4, a), similar to the results from B16 melanoma. As for H22 solid 
tumor cells, we found that 38.6% of them could form large clonal colonies in vitro. Also, 
the tumor cells from these colonies could generate new tumors in vivo when inoculated at 
relatively high doses (Fig. 4, b). Taken together, these results further suggested that the 
tumorigenic tumor cells is much higher than the number of CSCs, although the 
percentage of the tumorigenic tumor cells was varied among different tumor types. 
 
 
 
4. Discussion  
In this study, our results suggest that the number of tumor cells capable of 
generating a new tumor is higher than the number of CSCs. This was proved both in the 
theoretical calculation and in the 3 types of tumors we examined in our experiments. 
CSCs are a rare population, and they generally have higher tumorigenicity than other 
tumor cells, for example, they can self-renew and thus can preserve the stem cell 
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properties even after serial in vivo passage. Our results indicate that CSCs are not 
essential for tumor formation. Besides CSCs, more other tumor cells could generate a 
new tumor, even they could probably not self-renew. The difference between CSCs and 
other tumorigenic tumor cells is that CSCs can self-renew, and thus after serial in vivo 
passage, there are still CSCs in the tumor which can 're-initiate' a tumor, while other 
tumorigenic tumor cells might only generate one generation of tumor and probably no 
tumorigenic tumor cells exist in the generated tumor. 
 
 
Figure 4. Tumor formation by LLC and H22 tumor cells in an in vivo system. Mice were inoculated 
with LLC tumor cells (a) or H22 tumor cells (b) from different clonal colonies at the indicated doses. The 
mice were examined twice a week for tumors by observation and palpation for 18–100 days. The number 
of tumors that formed and the number of injections that were administered are indicated for each dose. 
 
 
Our results are in agreement with the results of two recent studies. One of them 
showed that nonirradiated congenic mice transplanted with as few as 10 or even 1 
unfractionated lymphoma cell developed tumors (8, 16), the other showed that more than 
one-fourth of the unselected melanoma cells from patients were tumorigenic (9). We 
speculate that in those studies even if CSCs were not present among the transplanted 
cells, but the transplanted cells had a high proliferation potential, i.e., they could undergo 
at least 30 divisions.  
Our results have important implications for tumor therapy, although more studies 
need to be done to prove our conclusion, for example, in other kinds of tumors, especially 
in human tumors. CSCs might be more resistant to chemotherapy than more differentiated 
cancer cells, and if they survive, they will continue the process of tumor growth and 
progression, or generate new tumors, termed recurrence or metastasis (1). Our results 
suggest that new tumors may be generated from not only CSCs, but any tumor cells with 
a high proliferation potential. Since we do not know whether there are any locations in the 
body where the microenvironment is suitable for the growth of such tumorigenic cells, just 
targeting the CSCs might not be sufficient. We should consider all tumor cells that have a 
high proliferation potential. During therapy, either all these tumor cells including CSCs 
should be eliminated or microenvironments that support the proliferation of these tumor 
cells should be destroyed. 
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